Mayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, Ronaldo Ismério Moreira, Iuri da Costa Leite, Marcelo Cunha, Pedro Henrique Amparo da Costa Leite, Carlos F Cáceres, Hamid Vega-Ramírez, Kelika A Konda, Juan Guanira, José Valdez Madruga, Sandra Wagner Cardoso, Marcos Benedetti, Maria Cristina Pimenta, Brenda Hoagland, Beatriz Grinsztejn, Valdilea Gonçalves Veloso
{"title":"拉丁美洲使用口服暴露前预防疗法(ImPrEP)的男男性行为者和变性女性中的细菌性传播感染:对一项前瞻性、开放标签、多中心研究的二次分析。","authors":"Mayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, Ronaldo Ismério Moreira, Iuri da Costa Leite, Marcelo Cunha, Pedro Henrique Amparo da Costa Leite, Carlos F Cáceres, Hamid Vega-Ramírez, Kelika A Konda, Juan Guanira, José Valdez Madruga, Sandra Wagner Cardoso, Marcos Benedetti, Maria Cristina Pimenta, Brenda Hoagland, Beatriz Grinsztejn, Valdilea Gonçalves Veloso","doi":"10.1016/S2352-3018(24)00211-X","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The global burden of sexually transmitted infections (STIs) poses a challenge in the context of HIV pre-exposure prophylaxis (PrEP) programmes. We aimed to explore factors associated with prevalent, incident, and recurrent STIs in men who have sex with men (MSM) and transgender women on PrEP in Brazil, Mexico, and Peru.</p><p><strong>Methods: </strong>ImPrEP was a prospective, single-arm, open-label, multicentre study that enrolled MSM and transgender women in the context of the public health systems of Brazil (14 sites), Mexico (four sites), and Peru (ten sites) between February, 2018, and June, 2021. Eligibility criteria followed regional PrEP guidelines at the study start, including participants aged 18 years and older, not living with HIV, and reporting at least one of the following in the previous 6 months: condomless anal sex (CAS), anal sex with partner(s) living with HIV, any bacterial STI, or transactional sex. Eligible participants were screened and enrolled on the same day to receive daily oral PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg). We assessed three outcomes: prevalent bacterial STIs, incident bacterial STIs, and recurrent bacterial STIs. Testing occurred at baseline and quarterly for syphilis, anorectal chlamydia, and anorectal gonorrhoea. Behavioural data were collected at baseline and quarterly. The study was registered with the Brazilian Registry of Clinical Trials, U1111-1217-6021.</p><p><strong>Findings: </strong>Among all 9509 participants included in the ImPrEP study (3928 [41·3%] in Brazil, 3288 [34·6%] in Mexico, and 2293 [24·1%] in Peru), 8525 (89·7%) had available STI results at baseline and were included in the prevalent STI analysis, and 7558 (79·5%) had available STI results during follow-up and were included in the incident and recurrent STI analyses. 2184 (25·6%) of 8525 participants had any bacterial STI at baseline. STI incidence during follow-up was 31·7 cases per 100 person-years (95% CI 30·7-32·7), with the highest rate for anorectal chlamydia (11·6 cases per 100 person-years, 95% CI 11·0-12·2), followed by syphilis (10·5 cases per 100 person-years, 9·9-11·1) and anorectal gonorrhoea (9·7 cases per 100 person-years, 9·2-10·3). Although only 2391 (31·6%) of 7558 participants had at least one STI during follow-up, 915 (12·1%) participants had recurrent diagnoses, representing 2328 (61·2%) of 3804 incident STI diagnoses. Characteristics associated with prevalent, incident, and recurrent STIs included younger age, multiple sex partners, receptive CAS, substance use, and previous STI diagnoses at baseline (incident or recurrent only).</p><p><strong>Interpretation: </strong>Our findings underscore the nuanced dynamics of STI transmission among MSM and transgender women across Latin America, highlighting an urgent need for tailored interventions to mitigate STI burden effectively, especially among the most susceptible individuals.</p><p><strong>Funding: </strong>Unitaid, WHO, and ministries of health (Brazil, Mexico, and Peru).</p><p><strong>Translations: </strong>For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e670-e679"},"PeriodicalIF":12.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442320/pdf/","citationCount":"0","resultStr":"{\"title\":\"Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study.\",\"authors\":\"Mayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, Ronaldo Ismério Moreira, Iuri da Costa Leite, Marcelo Cunha, Pedro Henrique Amparo da Costa Leite, Carlos F Cáceres, Hamid Vega-Ramírez, Kelika A Konda, Juan Guanira, José Valdez Madruga, Sandra Wagner Cardoso, Marcos Benedetti, Maria Cristina Pimenta, Brenda Hoagland, Beatriz Grinsztejn, Valdilea Gonçalves Veloso\",\"doi\":\"10.1016/S2352-3018(24)00211-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The global burden of sexually transmitted infections (STIs) poses a challenge in the context of HIV pre-exposure prophylaxis (PrEP) programmes. We aimed to explore factors associated with prevalent, incident, and recurrent STIs in men who have sex with men (MSM) and transgender women on PrEP in Brazil, Mexico, and Peru.</p><p><strong>Methods: </strong>ImPrEP was a prospective, single-arm, open-label, multicentre study that enrolled MSM and transgender women in the context of the public health systems of Brazil (14 sites), Mexico (four sites), and Peru (ten sites) between February, 2018, and June, 2021. Eligibility criteria followed regional PrEP guidelines at the study start, including participants aged 18 years and older, not living with HIV, and reporting at least one of the following in the previous 6 months: condomless anal sex (CAS), anal sex with partner(s) living with HIV, any bacterial STI, or transactional sex. Eligible participants were screened and enrolled on the same day to receive daily oral PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg). We assessed three outcomes: prevalent bacterial STIs, incident bacterial STIs, and recurrent bacterial STIs. Testing occurred at baseline and quarterly for syphilis, anorectal chlamydia, and anorectal gonorrhoea. Behavioural data were collected at baseline and quarterly. The study was registered with the Brazilian Registry of Clinical Trials, U1111-1217-6021.</p><p><strong>Findings: </strong>Among all 9509 participants included in the ImPrEP study (3928 [41·3%] in Brazil, 3288 [34·6%] in Mexico, and 2293 [24·1%] in Peru), 8525 (89·7%) had available STI results at baseline and were included in the prevalent STI analysis, and 7558 (79·5%) had available STI results during follow-up and were included in the incident and recurrent STI analyses. 2184 (25·6%) of 8525 participants had any bacterial STI at baseline. STI incidence during follow-up was 31·7 cases per 100 person-years (95% CI 30·7-32·7), with the highest rate for anorectal chlamydia (11·6 cases per 100 person-years, 95% CI 11·0-12·2), followed by syphilis (10·5 cases per 100 person-years, 9·9-11·1) and anorectal gonorrhoea (9·7 cases per 100 person-years, 9·2-10·3). Although only 2391 (31·6%) of 7558 participants had at least one STI during follow-up, 915 (12·1%) participants had recurrent diagnoses, representing 2328 (61·2%) of 3804 incident STI diagnoses. Characteristics associated with prevalent, incident, and recurrent STIs included younger age, multiple sex partners, receptive CAS, substance use, and previous STI diagnoses at baseline (incident or recurrent only).</p><p><strong>Interpretation: </strong>Our findings underscore the nuanced dynamics of STI transmission among MSM and transgender women across Latin America, highlighting an urgent need for tailored interventions to mitigate STI burden effectively, especially among the most susceptible individuals.</p><p><strong>Funding: </strong>Unitaid, WHO, and ministries of health (Brazil, Mexico, and Peru).</p><p><strong>Translations: </strong>For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.</p>\",\"PeriodicalId\":48725,\"journal\":{\"name\":\"Lancet Hiv\",\"volume\":\" \",\"pages\":\"e670-e679\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442320/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Hiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/S2352-3018(24)00211-X\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2352-3018(24)00211-X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:全球性传播感染(STI)的负担给艾滋病暴露前预防(PrEP)计划带来了挑战。我们旨在探讨巴西、墨西哥和秘鲁接受 PrEP 的男男性行为者(MSM)和变性女性的性传播感染流行率、发病率和复发率的相关因素:ImPrEP是一项前瞻性、单臂、开放标签、多中心研究,于2018年2月至2021年6月期间在巴西(14个研究点)、墨西哥(4个研究点)和秘鲁(10个研究点)的公共卫生系统中招募了男男性行为者和变性女性。资格标准遵循研究开始时的地区 PrEP 指南,包括年龄在 18 岁及以上、未感染 HIV 的参与者,以及在过去 6 个月中至少报告过以下情况之一的参与者:无安全套肛交 (CAS)、与感染 HIV 的伴侣发生肛交、任何细菌性 STI 或性交易。对符合条件的参与者进行筛查,并在同一天登记接受每日口服 PrEP(富马酸替诺福韦二吡呋酯 300 毫克和恩曲他滨 200 毫克)。我们评估了三项结果:细菌性 STI 流行、细菌性 STI 事件和细菌性 STI 复发。梅毒、肛门直肠衣原体和肛门直肠淋病的检测在基线时进行,每季度进行一次。行为数据在基线和每季度收集一次。该研究已在巴西临床试验注册中心(U1111-1217-6021)注册:在所有参与 ImPrEP 研究的 9509 名参与者中(巴西 3928 人[41-3%]、墨西哥 3288 人[34-6%]、秘鲁 2293 人[24-1%]),8525 人(89-7%)在基线时有性传播感染结果,被纳入流行性传播感染分析;7558 人(79-5%)在随访期间有性传播感染结果,被纳入偶发和复发性传播感染分析。8525名参与者中有2184人(25-6%)在基线时患有任何细菌性性传播感染。随访期间的性传播感染发病率为每 100 人年 31-7 例(95% CI 30-7-32-7),其中肛门直肠衣原体的发病率最高(每 100 人年 11-6 例,95% CI 11-0-12-2),其次是梅毒(每 100 人年 10-5 例,9-9-11-1)和肛门直肠淋病(每 100 人年 9-7 例,9-2-10-3)。虽然在 7558 名参与者中只有 2391 人(31-6%)在随访期间至少感染过一种性传播疾病,但有 915 人(12-1%)被诊断为复发性感染,占 3804 例性传播疾病事件诊断中的 2328 例(61-2%)。与性传播感染发病率、发病率和复发率相关的特征包括年龄较小、多个性伴侣、接受性 CAS、药物使用和基线时曾被诊断为性传播感染(仅为发病率或复发率):我们的研究结果强调了性传播感染在拉丁美洲男男性行为者和变性女性中传播的微妙动态,突出表明迫切需要采取有针对性的干预措施,以有效减轻性传播感染的负担,尤其是在最易受感染的人群中:资助:联合国艾滋病规划署、世界卫生组织、巴西、墨西哥和秘鲁卫生部:摘要的葡萄牙文和西班牙文译文见 "补充材料 "部分。
Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study.
Background: The global burden of sexually transmitted infections (STIs) poses a challenge in the context of HIV pre-exposure prophylaxis (PrEP) programmes. We aimed to explore factors associated with prevalent, incident, and recurrent STIs in men who have sex with men (MSM) and transgender women on PrEP in Brazil, Mexico, and Peru.
Methods: ImPrEP was a prospective, single-arm, open-label, multicentre study that enrolled MSM and transgender women in the context of the public health systems of Brazil (14 sites), Mexico (four sites), and Peru (ten sites) between February, 2018, and June, 2021. Eligibility criteria followed regional PrEP guidelines at the study start, including participants aged 18 years and older, not living with HIV, and reporting at least one of the following in the previous 6 months: condomless anal sex (CAS), anal sex with partner(s) living with HIV, any bacterial STI, or transactional sex. Eligible participants were screened and enrolled on the same day to receive daily oral PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg). We assessed three outcomes: prevalent bacterial STIs, incident bacterial STIs, and recurrent bacterial STIs. Testing occurred at baseline and quarterly for syphilis, anorectal chlamydia, and anorectal gonorrhoea. Behavioural data were collected at baseline and quarterly. The study was registered with the Brazilian Registry of Clinical Trials, U1111-1217-6021.
Findings: Among all 9509 participants included in the ImPrEP study (3928 [41·3%] in Brazil, 3288 [34·6%] in Mexico, and 2293 [24·1%] in Peru), 8525 (89·7%) had available STI results at baseline and were included in the prevalent STI analysis, and 7558 (79·5%) had available STI results during follow-up and were included in the incident and recurrent STI analyses. 2184 (25·6%) of 8525 participants had any bacterial STI at baseline. STI incidence during follow-up was 31·7 cases per 100 person-years (95% CI 30·7-32·7), with the highest rate for anorectal chlamydia (11·6 cases per 100 person-years, 95% CI 11·0-12·2), followed by syphilis (10·5 cases per 100 person-years, 9·9-11·1) and anorectal gonorrhoea (9·7 cases per 100 person-years, 9·2-10·3). Although only 2391 (31·6%) of 7558 participants had at least one STI during follow-up, 915 (12·1%) participants had recurrent diagnoses, representing 2328 (61·2%) of 3804 incident STI diagnoses. Characteristics associated with prevalent, incident, and recurrent STIs included younger age, multiple sex partners, receptive CAS, substance use, and previous STI diagnoses at baseline (incident or recurrent only).
Interpretation: Our findings underscore the nuanced dynamics of STI transmission among MSM and transgender women across Latin America, highlighting an urgent need for tailored interventions to mitigate STI burden effectively, especially among the most susceptible individuals.
Funding: Unitaid, WHO, and ministries of health (Brazil, Mexico, and Peru).
Translations: For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.
期刊介绍:
The Lancet HIV is an internationally trusted source of clinical, public health, and global health knowledge with an Impact Factor of 16.1. It is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice. The journal aims to provide a holistic view of the pandemic, covering clinical, epidemiological, and operational disciplines. It publishes content on innovative treatments and the biological research behind them, novel methods of service delivery, and new approaches to confronting HIV/AIDS worldwide. The Lancet HIV publishes various types of content including articles, reviews, comments, correspondences, and viewpoints. It also publishes series that aim to shape and drive positive change in clinical practice and health policy in areas of need in HIV. The journal is indexed by several abstracting and indexing services, including Crossref, Embase, Essential Science Indicators, MEDLINE, PubMed, SCIE and Scopus.